Irvine, California — October 16, 2025 — Leads & Copy — Biomerica, Inc. (Nasdaq: BMRA) has announced a marketing services arrangement with Henry Schein, Inc. (Nasdaq: HSIC) to market Biomerica’s inFoods® Irritable Bowel Syndrome (IBS) test in the United States, excluding New York State.
Henry Schein’s distribution network will provide marketing support for the inFoods® IBS test to primary care and gastroenterology specialty practices. Zack Irani, CEO of Biomerica, expressed enthusiasm for the partnership, highlighting Henry Schein’s reach and track record. Ty Ford, Vice President and General Manager of Sales for Henry Schein Medical, emphasized the company’s dedication to offering innovative solutions for healthcare professionals.
A multicenter, double-blinded clinical study on the inFoods® IBS test was published in Gastroenterology, demonstrating statistically significant outcomes. The study, conducted at institutions including Cleveland Clinic and Mayo Clinic, showed that 59.6% of patients in the treatment group achieved the FDA’s endpoint for abdominal pain reduction, compared to 42.2% in the control group.
Irritable bowel syndrome (IBS) affects about 10% to 15% of adults in the United States. The inFoods® IBS test identifies patient-specific food triggers responsible for symptoms such as abdominal pain, bloating, diarrhea, and constipation, offering a non-pharmaceutical, precision-based approach to symptom relief.
For more information about inFoods® IBS, visit www.inFoodsibs.com.
About Henry Schein, Inc. (Nasdaq: HSIC): Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for health care professionals powered by a network of people and technology. With more than 25,000 Team Schein Members worldwide, the Company’s network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our Business, Clinical, Technology, and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites.
Henry Schein operates through a centralized and automated distribution network, with a selection of more than 300,000 branded products and Henry Schein corporate brand products in our distribution centers.
About Biomerica (NASDAQ: BMRA): Biomerica, Inc. (www.biomerica.com) is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (in home and in physicians’ offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases.
Corporate Contact:
Zack Irani | CEO
p. 949.645.2111
Source: Biomerica
